Microbiotix, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Microbiotix, Inc. – Product Pipeline Review – 2016’, provides an overview of the Microbiotix, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Microbiotix, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Microbiotix, Inc.

The report provides overview of Microbiotix, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Microbiotix, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Microbiotix, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Microbiotix, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Microbiotix, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Microbiotix, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Microbiotix, Inc. Snapshot 7

Microbiotix, Inc. Overview 7

Key Information 7

Key Facts 7

Microbiotix, Inc. - Research and Development Overview 8

Key Therapeutic Areas 8

Microbiotix, Inc. - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Microbiotix, Inc. - Pipeline Products Glance 13

Microbiotix, Inc. - Clinical Stage Pipeline Products 13

Phase I Products/Combination Treatment Modalities 13

Microbiotix, Inc. - Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

Microbiotix, Inc. - Drug Profiles 16

filociclovir 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

MBX-700 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

MBX-500 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

MBX-701 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

MBX-900 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Small Molecules to Inhibit 16S rRNA for Tuberculosis 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Small Molecules to Inhibit T3SS for Pseudomonas Aeruginosa Infections 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

KKL-35 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

MBX-2168 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

MBX-2319 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

MBX-2329 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

MBX-2359 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

MBX-2402 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

MBX-2546 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecule to Inhibit DNA Helicase for Infectious Diseases 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecules for Ebola Virus Infection 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecules for Fungal Infections 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecules for Gram-Negative Bacterial Infections 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecules to Inhibit bNOS for MRSA Infections 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecules to Inhibit BoNT/A LC for Botulism 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecules to Inhibit DNA Synthesis for Gram-Negative and Gram-Positive Bacterial Infections 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecules to Inhibit NPC1 for Filovirus Infections 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecules to Inhibit PSAC for Malaria 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecules to Inhibit the Fatty Acid Synthesis II for Pseudomonas Aeruginosa Infections 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Microbiotix, Inc. - Pipeline Analysis 45

Microbiotix, Inc. - Pipeline Products by Target 45

Microbiotix, Inc. - Pipeline Products by Route of Administration 46

Microbiotix, Inc. - Pipeline Products by Molecule Type 47

Microbiotix, Inc. - Pipeline Products by Mechanism of Action 48

Microbiotix, Inc. - Dormant Projects 49

Microbiotix, Inc. - Locations And Subsidiaries 50

Head Office 50

Appendix 51

Methodology 51

Coverage 51

Secondary Research 51

Primary Research 51

Expert Panel Validation 51

Contact Us 51

Disclaimer 52

List of Tables

List of Tables

Microbiotix, Inc., Key Information 7

Microbiotix, Inc., Key Facts 7

Microbiotix, Inc. – Pipeline by Indication, 2016 9

Microbiotix, Inc. – Pipeline by Stage of Development, 2016 11

Microbiotix, Inc. – Monotherapy Products in Pipeline, 2016 12

Microbiotix, Inc. – Phase I, 2016 13

Microbiotix, Inc. – Preclinical, 2016 14

Microbiotix, Inc. – Discovery, 2016 15

Microbiotix, Inc. – Pipeline by Target, 2016 45

Microbiotix, Inc. – Pipeline by Route of Administration, 2016 46

Microbiotix, Inc. – Pipeline by Molecule Type, 2016 47

Microbiotix, Inc. – Pipeline Products by Mechanism of Action, 2016 48

Microbiotix, Inc. – Dormant Developmental Projects,2016 49

List of Figures

List of Figures

Microbiotix, Inc. – Pipeline by Top 10 Indication, 2016 9

Microbiotix, Inc. – Pipeline by Stage of Development, 2016 11

Microbiotix, Inc. – Monotherapy Products in Pipeline, 2016 12

Microbiotix, Inc. – Pipeline by Top 10 Target, 2016 45

Microbiotix, Inc. – Pipeline by Route of Administration, 2016 46

Microbiotix, Inc. – Pipeline by Molecule Type, 2016 47

Microbiotix, Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 48

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports